GlassScriptPhysician profile
Chheng Ly
NPI 1235738204
$2,093.18
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,028 · 2022: $853 · 2023: $181 · 2024: $30.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $212.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $339.94 | 2021-2022 | |
| Novo Nordisk INC | $338.48 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $261.78 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $232.39 | 2021-2022 | |
| Almatica Pharma LLC | $155.52 | 2021-2024 | Loreev Xr, Sertraline Hcl |
| Takeda Pharmaceuticals U.S.A., INC. | $152.70 | 2021-2022 | |
| Abbvie INC. | $122.72 | 2023 | |
| Alkermes, INC. | $88.01 | 2022 | |
| Janssen Pharmaceuticals, INC | $76.02 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $65.92 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $65.61 | 2021-2022 | |
| Amarin Pharma, INC. | $60.88 | 2021 | |
| Lilly USA, LLC | $35.64 | 2021 | |
| Glaxosmithkline, LLC. | $24.20 | 2021 | |
| Lundbeck LLC | $23.39 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $19.20 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.07 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chheng Ly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.